Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma

Nucleosides, Nucleotides and Nucleic Acids

Volumn 29, Issue 4-6, 2010, Pages 352-358

  He, E ^a   Xu, X H ^b   Guan, H ^c   Chen, Y ^d   Chen, Z H ^e   Pan, Z L ^f   Tang, L L ^g   Hu, G Z ^h   Li, Y ^a   Zhang, M ^a   Zhou, J ^a   Eriksson, S ⁱ   Fornander, T ^j   Skog, S ^a  

^a Sino Swed Molecular Bio Medicine Research Institute   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c Shenzhen Second Hospital   (China)

^d Fujian Cancer Hospital   (China)

^e THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^f No 411 Hospital of PLA   (China)

^g CENTRAL SOUTH UNIVERSITY   (China)

^h Jiangxi People's Hospital   (China)

ⁱ SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

immunohistochemistry; malignancies; serum; Thymidine kinase 1

Indexed keywords

ANTINEOPLASTIC AGENT; THYMIDINE KINASE 1;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOLUMINESCENCE; DISEASE MARKER; DNA REPLICATION; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE;

BREAST NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; PROGNOSIS; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 77953698379     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257771003738535     Document Type: Article

References (10)

1. He, Q.; Wang, N.; Skog, S.; Ericsson, S.; Tribukait, B. Characterisation of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Europ. J. Cell Biol. 1996, 70, 117-124.
2. Wu, C.; Yang, R.; Zhou, J.; Bao, S.; Zou, L.; Mao, Y.; He, Q. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J. Immuno. Method 2003, 277, 157-169.
3. He,Q.; Zou, L.; Zhang, P.; Liu, J.; Skog, S.; Fonander, T. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. Internal. J. Biol. Marker 2000, 15, 139-146.
4. Greene, F.L.; Page, D.L.; Fleming, I.D.; et al. AJCC Cancer Staging Manual; Springer-Verlag, New York, 2002.
5. Guan, H.; Sun, Y.; Zan, Q.; Xu, M.; Li, Y.; Zhou, J.; He, E.; Eriksson, S.; Wen, W.; Skog, S. Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: a useful tool in tumour therapy management. Mol. Med. Reports 2009, 2, 923-929.
6. HengZhi, C.; Zhou, H.; Tian, N.B.; He, E.; Skog, S. Serological thymidine kinase 1 (STK1) indicate an elevated risk for development of malignant tumors. Anticancer Res. 2008, 28, 3897-3908.
7. Xing-Hua, Z.; Jin-Rong, Y.; Xian-Yan, F.; Lei, Q.; Hai-Yin, L.; Hai-Xia, W.; Xia, Y.; Bo, S.; Ming, Z.; He, E.; Skog, S. The significance of serum thymidine kinase 1 for the risk screening of cancer development of pre-cancerous diseases-an analysis of the Jilin Oilfield 8869 healthy screening. Chin. J. Health Manage. 2010, 4, 35-38.
8. He, Q.; Fornander, T.; Johansson, H.; Johansson, U.; Hu, G.Z.; Rutqvist, L.E.; Skog, S. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 2006, 26, 4753-4759.
9. Topolan, O.; Holubec, L. The role of thymidine kinase in cancer disease. Expert Opinion 2008, 2, 129-141.
10. Broet, P.; Romain, S.; Daver, A.; et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J. Clin. Oncol. 2000, 19, 2778-2787.